Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis

Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis

Abstract Aims This systematic review and meta-analysis aimed to compare the overall and site-specific cancer risk associated with SGLT2i versus DPP4i in patients with type 2 diabetes mellitus. Methods We systematically searched PubMed, Scopus, and Web of Science for cohort studies comparing cancer i...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hamed Hajishah, Parsa Mazloom, Amirhossein Salehi, Danial Kazemi, Reza Samiee, Hossein Majlesi, Mohammad Javad Amini, Arefeh Meyari, Negin Safari Dehnavi, Masood Zangi
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Series:	Diabetology & Metabolic Syndrome
Subjects:	Sodium-Glucose transporter 2 inhibitors Dipeptidyl-Peptidase IV inhibitors Diabetes mellitus, type 2 Neoplasms
Online Access:	https://doi.org/10.1186/s13098-025-01898-z
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications
by: Yaswanth Kuthati, et al.
Published: (2025-04-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Angioedema following venipuncture in a patient on angiotensin‐converting enzyme inhibitor and dipeptidyl peptidase‐IV inhibitor therapy: A case report
by: Adrien Bénic, et al.
Published: (2025-06-01)

Cardiovascular Events and Heart Failure in Patients With Type 2 Diabetes Treated With Dipeptidyl Peptidase-4 Inhibitors: A Meta-Analysis
by: Adili Tuersun, PhD, et al.
Published: (2025-01-01)

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
by: M Elle Saine, et al.
Published: (2015-04-01)

Research progress on the association of bullous pemphigoid with type 2 diabetes mellitus
by: ZHANG Ruohan, et al.
Published: (2025-03-01)

Impact of Dipeptidyl Peptidase-4 Inhibitors on Aminotransferases Levels in Patients with Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trial
by: Gang Ma, MD, et al.
Published: (2025-01-01)

Study on Anti-inflammatory and Anti-oxidative Stress Mechanism of Sitagliptin: a Dipeptidyl Peptidase-4 Inhibitor
by: ZHU Jing, XIE Ji, HU Xiaoxia
Published: (2025-04-01)

Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study
by: Oscar Hou‐In Chou, et al.
Published: (2025-06-01)

Role of DPP-4 and NPY Family Peptides in Gastrointestinal Symptoms Associated with Obesity and Type 2 Diabetes Mellitus
by: Mantas Malinauskas, et al.
Published: (2025-03-01)

Dataset on effect of cadmium and lead on chemical reactivity of selected heterocyclic compounds as potential dipeptidyl peptidase III inhibitors using insilico methodMendeley Data
by: Kehinde Adeola Bolaji, et al.
Published: (2025-06-01)

Elimination of hepatocyte‐derived DPP4 downregulates cardiac immune‐ and collagen‐related genes but does not alter cardiac function in aged male mice
by: Natasha A. Trzaskalski, et al.
Published: (2025-08-01)

Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study
by: Yu-Ching Li, et al.
Published: (2025-04-01)

Assessment of the effectiveness and safety of fixed-dose combination of alogliptin and pioglitazone in real clinical practice: results of the PROsperity study
by: M. V. Shestakova, et al.
Published: (2025-05-01)

Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: mechanisms, clinical trials, and therapeutic prospects
by: Dandan Zhang, et al.
Published: (2025-08-01)

Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
by: Gail Mkele
Published: (2013-12-01)

Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study
by: Makoto Ohara, et al.
Published: (2025-04-01)

Targeting dipeptidyl peptidase-8/9 to combat inflammation-induced osteoclastogenesis in RAW264.7 macrophages and analysis of anti-osteoclastogenesis potential of chrysin
by: Syed Sufian Ahmad, et al.
Published: (2025-04-01)

FEATURES ENZYMATIC RELEASE BIOCOMPATIBLE MICROCAPSULES WITH BUILT-IN SHELL INHIBITOR PEPTIDASE
by: E. V. Popova, et al.
Published: (2019-01-01)

Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
by: Qin Li, et al.
Published: (2025-07-01)

Development and Validation of a Highly Sensitive LC–MS/MS Method for the Precise Quantification of Sitagliptin in Human Plasma and Its Application to Pharmacokinetic Study
by: Yuna Song, et al.
Published: (2025-07-01)

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01)

Deciphering new biomolecules, antioxidants, and human dipeptidyl Peptidase-4 inhibitor potential of green celery: Bioprospecting insights from molecular docking and in vitro investigation
by: Fan Maitri Aldian, et al.
Published: (2025-10-01)

Frailty-stratified effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors and GLP-1 receptor agonists on pulmonary outcomes in type 2 diabetes: a nationwide cohort studyResearch in context
by: Lin-Chieh Meng, et al.
Published: (2025-07-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Serum FGF23 and DPP4 Levels as Biomarkers for Coronary Artery Disease Severity in Type 2 Diabetic Patients with Coronary Heart Disease
by: Zhong X, et al.
Published: (2025-03-01)

Pathogen Enzyme-Mediated Alkoxyamine Homolysis as a Killing Mechanism of <i>Aspergillus fumigatus</i>
by: Marion Filliâtre, et al.
Published: (2025-07-01)

Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
by: Ji Yun Lee, et al.
Published: (2025-07-01)

Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01)

SGLT2 inhibitor administration to two patients with diabetes mellitus with ascites due to cirrhosis
by: Koji Nagayama, et al.
Published: (2025-07-01)

SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges
by: Taimin Luo, et al.
Published: (2025-07-01)

Progress in studies on renal effects and molecular mechanism of SGLT-2 inhibitors
by: XING Bei, et al.
Published: (2020-01-01)

Protein hydrolysate as a source of bioactive peptides in diabetic food products
by: O. V. Zinina, et al.
Published: (2024-01-01)

Bio-Adrenomedullin and Dipeptidyl Peptidase 3 as Novel Sepsis Biomarkers in the Emergency Department and the Intensive Care Unit: A Narrative Review
by: Ioannis Ventoulis, et al.
Published: (2025-06-01)

SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
by: Marlena Stielow, et al.
Published: (2025-07-01)

Profiling of proteases involved in SARS-CoV-2 pathogenesis in human saliva: Influence of age and gender
by: Mentalla Motaz Abdellatif, et al.
Published: (2025-09-01)